Pevion Biotech Ag
BERN, Switzerland, October 11, 2011 -
Pevion Biotech AG today announced latest results from the ongoing clinical study of its therapeutic Candida vaccine PEV7, showing high levels of specific antibodies and a 100% mucosal immune response rate.
BERN, Switzerland, September 1, 2011 -
Pevion Biotech AG today announced that the company has granted to CSL Limited a right of first refusal for the commercialization of its therapeutic Candida vaccine in Australia and New Zealand.
BERNE, Switzerland, April 21, 2011 - Pevion Biotech AG today announced that Jean-Paul Prieels has joined its
Board of Directors.
ITTIGEN, Switzerland and BERN, Switzerland, February 10, 2011 - Pevion Biotech Ltd.
ITTIGEN and BERN, Switzerland, November 11, 2010 - Pevion Biotech AG today announced positive preliminary results from a
Phase I study of PEV7, the first vaccine against recurrent vulvovaginal
candidiasis (RVVC).
